Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$602.7
−$1.55 · -0.26%
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Previous close
$602.7
−$1.55 · -0.26%
After-hours
$602.7
$0.00 · 0.00%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Day range
Current $602.7
52-week range
Current $602.7
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
74
Undervalued
Sentiment
59
Mixed
Risk
35
Moderate Risk
Momentum
51
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Day range
Current $602.7
52-week range
Current $602.7
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.53B USD | 2.11B USD | 1.89B USD | 1.46B USD | 1.14B USD |
| Cost of goods sold | 1.77B USD | 1.45B USD | 1.36B USD | 1.03B USD | 814.22M USD |
| Gross profit | 760.62M USD | 656.31M USD | 524.51M USD | 432.44M USD | 328.16M USD |
| Selling, general, and administrative | 197.56M USD | 180.18M USD | 161.35M USD | 131.4M USD | 108.42M USD |
| Operating expenses | 225.68M USD | 209.44M USD | 187.68M USD | 153.74M USD | 129.54M USD |
| Interest income | — | 25M USD | — | — | — |
| Interest expense | — | — | 488K USD | 2.91M USD | 105K USD |
| Depreciation and amortization | 28.12M USD | 29.25M USD | 26.33M USD | 22.34M USD | 21.12M USD |
| Operating income | 534.94M USD | 446.87M USD | 336.83M USD | 278.7M USD | 198.62M USD |
| Net income | 451.12M USD | 404.39M USD | 282.81M USD | 245.37M USD | 181.85M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI431.46M0.02%2.3T USD0.03%$379.56-0.39%
Vanguard Morningstar Small-Cap ETFVB312.25M0.17%185.3B USD0.03%$287.63+0.23%
Invesco S&P MidCap Quality ETFXMHQ198.37M3.68%5.38B USD0.30%$113.66+0.90%
Vanguard Morningstar Small-Cap Growth ETFVBK179.22M0.39%44.7B USD0.05%$340.59-0.48%
Vanguard Extended Market ETFVXF155.72M0.16%95.4B USD0.05%$233.13-0.15%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY103.46M0.40%25.53B USD0.23%$666.26+0.35%
iShares Biotechnology ETFIBB102.73M0.99%10.41B USD0.44%$200.48-1.41%
iShares Russell Mid-Cap Growth ETFIWP76.78M0.39%19.88B USD0.23%$140.9-0.40%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBInvesco S&P MidCap Quality ETFXMHQVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR S&P MIDCAP 400 ETF TrustMDYiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
